Abstract
CONTEXT
Cardiovascular disease is increased in patients with human immunodeficiency virus (HIV), but the specific mechanisms are unknown.
OBJECTIVE
To assess arterial wall inflammation in HIV, using 18fluorine-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET),
in relationship to traditional and nontraditional risk markers, including soluble CD163 (sCD163), a marker of monocyte and
macrophage activation.
DESIGN, SETTING, AND PARTICIPANTS
A cross-sectional study of 81 participants investigated between November 2009 and July 2011 at the Massachusetts General Hospital.
Twenty-seven participants with HIV without known cardiac disease underwent cardiac 18F-FDG-PET for assessment of arterial
wall inflammation and coronary computed tomography scanning for coronary artery calcium. The HIV group was compared with 2
separate non-HIV control groups. One control group (n = 27) was matched to the HIV group for age, sex, and Framingham risk
score (FRS) and had no known atherosclerotic disease (non-HIV FRS-matched controls). The second control group (n = 27) was
matched on sex and selected based on the presence of known atherosclerotic disease (non-HIV atherosclerotic controls).
MAIN OUTCOME MEASURE
Arterial inflammation was prospectively determined as the ratio of FDG uptake in the arterial wall of the ascending aorta
to venous background as the target-to-background ratio (TBR).
RESULTS
Participants with HIV demonstrated well-controlled HIV disease (mean [SD] CD4 cell count, 641 [288] cells/μL; median [interquartile
range] HIV-RNA level, <48 [<48 to <48] copies/mL). All were receiving antiretroviral therapy (mean [SD] duration, 12.3 [4.3]
years). The mean FRS was low in both HIV and non-HIV FRS-matched control participants (6.4; 95% CI, 4.8-8.0 vs 6.6; 95% CI,
4.9-8.2; P = .87). Arterial inflammation in the aorta (aortic TBR) was higher in the HIV group vs the non-HIV FRS-matched
control group (2.23; 95% CI, 2.07-2.40 vs 1.89; 95% CI, 1.80-1.97; P < .001), but was similar compared with the non-HIV atherosclerotic
control group (2.23; 95% CI, 2.07-2.40 vs 2.13; 95% CI, 2.03-2.23; P = .29). Aortic TBR remained significantly higher in the
HIV group vs the non-HIV FRS-matched control group after adjusting for traditional cardiovascular risk factors (P = .002)
and in stratified analyses among participants with undetectable viral load, zero calcium, FRS of less than 10, a low-density
lipoprotein cholesterol level of less than 100 mg/dL (<2.59 mmol/L), no statin use, and no smoking (all P ≤ .01). Aortic TBR
was associated with sCD163 level (P = .04) but not with C-reactive protein (P = .65) or D-dimer (P = .08) among patients with
HIV.
CONCLUSION
Participants infected with HIV vs noninfected control participants with similar cardiac risk factors had signs of increased
arterial inflammation, which was associated with a circulating marker of monocyte and macrophage activation.
Links
Authors
Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vijayakumar J, Corsini E, Abdelbaky A, Zanni MV, Hoffmann U, Williams KC, Lo J, Grinspoon SK
Institution
MR-PET-CT Program and Department of Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA.
Source
JAMA : the journal of the American Medical Association 308:4 2012 Jul 25 pg 379-86MeSH
Antigens, CDAntigens, Differentiation, Myelomonocytic
Aorta
Biological Markers
Cardiovascular Diseases
Case-Control Studies
Cross-Sectional Studies
Female
Fluorodeoxyglucose F18
HIV Infections
Humans
Inflammation
Macrophage Activation
Male
Middle Aged
Monocytes
Positron-Emission Tomography
Receptors, Cell Surface
Risk Factors
Pub Type(s)
Journal ArticleResearch Support, N.I.H., Extramural
Language
eng
PubMed ID
22820791
Log In

